These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Survey of adults living with epilepsy in Hungary: health-related quality of life and costs].
    Author: Péntek M, Bereczki D, Gulácsi L, Mikudina B, Arányi Z, Juhos V, Baji P, Brodszky V.
    Journal: Ideggyogy Sz; 2013 Jul 30; 66(7-8):251-61. PubMed ID: 23971356.
    Abstract:
    BACKGROUND AND PURPOSE: Disease burden of epilepsy in Hungary is underexplored. The aim of our study was to assess the quality of life and costs of adults with epilepsy. METHODS: Cross-sectional questionnaire survey was performed in two hospital based outpatient neurology centres involving consecutive patients with epilepsy. Demography, clinical characteristics, health status (EQ-5D) and health care utilisation in the past 12 months were surveyed. Cost calculation was performed from the societal perspective. RESULTS: Altogether 100 patients (women 58%) were involved, their mean age was 37.6 (SD = 12.5) years. Disease duration was 15.0 (SD = 12.1) years on average and 22 (22%) patients were disability pensioners. The EQ-5D score was mean 0.83 (SD = 0.24) which is significantly lower than the age-matched population norm (p = 0.017). Pain/discomfort and anxiety/depression are the most problematic health dimensions. The annual cost per patient was mean 2421 (SD = 3249) Euros (679 397 SD = 911 783 HUF; conversion: 1 Euro = 280.6 HUF), distribution between direct medical, direct non-medical and indirect costs was 33%, 18% or 49%. Patients with seizure in the past 12 months have higher cost on avergare than the asymptomatic subsample (3119 vs. 988 Euros/patient/year; 935 481 vs. 277 209 HUF/patient/year). CONCLUSION: Adults with epilepsy have significantly worse health status by the EQ-5D than the gender and age matched Hungarian general population. Disease related costs are significant especially in cases with seizure, productivity loss related costs are dominant. Our study provides basic data for clinical and sustainable health care financing decisions.
    [Abstract] [Full Text] [Related] [New Search]